Page 60 - GPD-3-2

Gene & Protein in Disease TOPK: Target for lung cancer treatment

whose prognostic data were unavailable. In addition, in 4. TOPK and treatment of lung cancer
26
27
a pan cancer analysis, Ma et al. indicated that TOPK was
upregulated significantly in LUAD patients, indicating Surgery is the predominant treatment choice for early-stage
lung cancer patients, significantly raising their survival
a poor prognosis. Taken together, TOPK is a potential rate. Patients in the middle to late stages of the disease
prognostic marker for lung cancer, especially LUAD. require comprehensive treatment. Traditional treatment
3. TOPK signaling pathway in lung cancer for advanced lung cancer mainly relies on radiotherapy and
chemotherapy, which have poor efficacy. Approximately
28
TOPK is involved in many biological functions of cells. 65% of patients are diagnosed with locally advanced lung
It also promotes the occurrence, metastasis, metastasis cancer, and the 5-year survival rate is approximately 20%.
development, and drug resistance of lung cancer cells and Thus, designing effective strategies for preventing and
serves as a marker for the diagnosis and prognosis of lung treating advanced lung cancers that are associated with low
cancer. Research has shown that its function is regulated patient survival rates is the major focus of research. 29
by a variety of upstream and downstream molecules, TOPK has attracted the interest of many researchers
making it a linchpin in the tumor signaling network. and clinicians as a potential therapeutic target, and the
12
In lung cancer, TOPK is directly or indirectly regulated investigations on TOPK inhibitors have been ongoing. It
by important targets such as MET, ALK, and EGFR, has been reported that some small molecule compounds
22
5
17
and the phosphorylation of TOPK activates downstream and FDA-approved drugs, such as HI-032, OTS964,
30
17
signaling pathways, leading to the occurrence, progression, OTS514, 18 SKLB-C05, 31 3-deoxysappanchalcone, 32,33
or drug resistance of lung cancer (Figure 2). These studies ADA-07, eupafolin, acetylshikonin, glycycoumarin,
34
34
36
35
suggest that as a kinase in the signaling network, TOPK is pantoprazole, 37 ilaprazole, 38 fucoidan, 39 baicalin,
40
a promising therapeutic target for lung cancer. cefradine, 41 sulfasalazine, 42 coffee phenolic

Figure 2. TOPK signaling pathway in lung cancer. Source: Schematic diagram made by the authors.
Abbreviation: TOPK: T-LAK cell-originated protein kinase.

Volume 3 Issue 2 (2024) 4 doi: 10.36922/gpd.3062